Acitretin exhibits inhibitory effects towards UDP-glucuronosyltransferase (UGT)1A9-mediated 4-methylumbelliferone (4-MU) and propofol glucuronidation reaction

Pharmazie

Volumn 68, Issue 6, 2013, Pages 449-452

  Yu, Ming Lian ^a   Yang, Yue ^b   Wang, Cong Min ^a   Zhang, Meng Meng ^c   Bai, Miao Chun ^a   Guo, Yue Ling ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; HYMECROMONE; PROPOFOL;

ARTICLE; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION;

ACITRETIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; ISOENZYMES; KERATOLYTIC AGENTS; KINETICS; LIVER; MICROSOMES, LIVER; PROPOFOL;

EID: 84880489234     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.2816     Document Type: Article

References (14)

1. Ellis CN, Voorhees JJ (1987) Etretinate therapy. J Am Acad Dermatol 16: 267-291.
2. Lucek RW, Colburn WA (1985) Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet 10: 38-62.
3. Ferrari M, Martignoni E, Blandini F, Riboldazzi G, Bono G, Marino F, Cosentino M (2012) Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients. Eur J Clin Pharmacol 68: 1493-1499.
4. Gong G, Zhang SY, Lin JJ, Cai L, Wang Q, Ma R, Zhang Y, Tu Y (2012) Dihydrotanshinone I exhibits strong inhibition towards UDP- glucuronosyltransferase (UGT) 1A7. Lat Am J Pharm 31: 1060-1063.
5. Hao M, Zhao Y, Chen P, Huang H, Liu H, Jiang H, Zhang R, Wang H (2008) Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One 3: e2697.
6. Kakkar T, Boxenbaum H, Mayersohn M (1999) Estimation of Ki in a competitive enzyme-inhibition model: Comparisons among three methods of data analysis. Drug Metab Dispos 27: 756-762.
7. Mackenzie PI (2000) Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 22: 10-13.
8. Rowland A, Knights KM, Mackenzie PI, Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36: 1056-1062.
9. Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D (2006) Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 154: 325-331.
10. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, Manns MP(2002) Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50: 259-265.
11. Stuck AE, Brindley CJ, Busslinger A, Frey FJ (1989) Pharmacokinetics of acitretin and its 13-cis metabolite in patients on haemodialysis. Br J Clin Pharmacol 27: 301-304.
12. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67: 191-199.
13. Vree TB, Lagerwerf AJ, Bleeker CP, deGrood PM (1999) Direct highperformance liquid chromatography determination of propofol and its metabolite quinol with their glucuronide conjugates and preliminary pharmacokinetics in plasma and urine of man. J Chromatogr B Biomed Sci Appl 721: 217-228.
14. Xing J, Che W (2012) 20(S)-Protopanaxatriol (Ppt) exhibits inhibition towards UDP-glucuronosyltransferase (UGT)-catalyzed zidovudine glucuronidation. Lat Am J Pharm 31: 628-631.